Hints and tips:
Related Special Reports
Drugmaker’s chief executive Pascal Soriot had talks last year about a role with US group Biogen
...Janssen is the pharmaceutical division of J&J....
...Not only was the BioNTech/Pfizer vaccine the first to be deployed but it has suffered less from rare side effects and manufacturing glitches than its big western rivals Oxford/AstraZeneca, Janssen or Moderna...
...A booster shot of Johnson & Johnson’s Covid-19 vaccine produced a strong and rapid antibody response against the virus, the pharmaceutical company said on Wednesday....
...Rivals AstraZeneca, Johnson & Johnson, Russia’s Sputnik V and new entrants such as Novavax make up the remainder of the market, which is forecast to double in value to $124bn next year....
...But in March, as the pandemic hit hospital wards around Pfizer’s Manhattan headquarters, the two companies announced a collaboration....
...“The Janssen vaccine will be another weapon in our arsenal to beat this pandemic,” said vaccines minister Nadhim Zahawi....
...Several companies in India, a global pharmaceuticals hub, have signed on to manufacture Sputnik V....
FDA will now weigh whether to allow use of first single-dose jab to prevent the virus
..., J&J’s pharmaceutical division, told the panel on Friday: “Janssen’s vaccine candidate would play a critical role in the global efforts to fight Covid-19 . . ....
...“Africa is a key market for Sputnik V,” said the Russian Direct Investment Fund, a Kremlin-run wealth fund overseeing Sputnik V’s foreign sales....
...“At present, no clear causal relationship has been established between these rare events and the Janssen [J&J] Covid-19 vaccine,” it said, adding that it was working closely with experts and regulators to...
...Top Indian pharmaceutical companies have tie-ins for local production of other globally approved vaccines, like Russia’s Sputnik V, but regulators want local “bridging studies” to gauge their effectiveness...
...J&J is preparing to test a new formulation that could be targeted at the 501.v2 variant, but Mathai Mammen, global head of research and development for Janssen, J&J’s pharmaceuticals division, said he was...
...“The acquisition was driven by the significant opportunity seen in nipocalimab, along with the scientific capability Janssen is acquiring with the Momenta team,” J&J said in a statement....
...Through its Janssen subsidiary, the New Jersey-based drugmaker will administer its experimental vaccine to 6,000 UK volunteers in two doses in a phase-3 trial....
...Dr Fischer and other experts may be trying to be transparent so as to build confidence, according to sociologist Jeremy Ward....
...programme on Sunday morning with elderly patients and medical staff in Sevran near Paris — the first to receive the injection was Mauricette, a 78-year-old retired cleaning lady — to be followed by a geriatric ward...
...After such strong reads from the first two releases (three if we count Russia’s Sputnik V), the disappointing AZN figures were perhaps bound to prompt downward pressure on the company’s shares....
...In August, Russia became the first country to approve a Covid-19 vaccine — named Sputnik V — for civilian use, but western experts cast doubt on its efficacy and safety....
...“This is about getting the best possible information into the clinical teams who save lives on wards.”...
...From a young age, she would follow him as he did his rounds through the wards of his hospital in Lower Saxony, and even into the operating theatre....
...If there is a sense from this earnings season that confidence in a V-shaped recovery for profits is misplaced, then the impact will probably be hardest on companies with weak balance sheets, and on those...
...He hopes if treated early, the patients will recover rapidly and open up room in the wards....
...He joined Janssen, J&J’s pharma division, in sales in 1988, with only a BA in biology....
International Edition